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INTRODUCTION
The mechanisms by which endometriosis impairs fertili-
ty, as well as the etiologic factors responsible for its histoge-
nesis and progression, remain poorly understood. There is
growing evidence that the eutopic endometrium of women
with endometriosis is different from that of women without
endometriosis. Some of these differences may be related to
failure of implantation, while others may contribute to the
establishment and growth of endometriotic lesions (1-4). 
Angiogenin is a heparin-binding 14.1-kDa single chain
polypeptide that has been shown to have a higher angiogenic
activity than other angiogenic factors (5). Angiogenin is
expressed in human endometrium, with enhanced expres-
sion during the secretory phase, and in decidual tissues, rais-
ing the possibility that angiogenin may play a role in estab-
lishing pregnancy (6). Based upon the specific enhancement
of angiogenin expression around the implantation window
period along with its strong angiogenic activity, it is neces-
sary to investigate whether the expression of angiogenin in
the eutopic endometrium is different between women with
and without endometriosis. This study was designed to com-
pare the level of angiogenin expression in the eutopic endo-
metrium from women with and without endometriosis by
utilizing real-time polymerase chain reaction (PCR).
MATERIALS AND METHODS
Patients and samples
Endometrial tissues were obtained from a total of 61 patients
who had undergone gynecological operations in their repro-
ductive ages. Thirty-two patients had laparoscopic and his-
tological evidence of advanced stage endometriosis, while
29 patients with proven fertility without the disease served
as controls. The number of 30 patients for each group was
initially chosen to detect a difference of 4.0 in the secretory
phase between the two groups, assuming that a standard
deviation is 4.0 and about half of the subjects are in the secre-
tory phase, with a power of 0.8 for p<0.05. In the endometrio-
sis group, the extent of disease was staged according to the
American Society for Reproductive Medicine (1997) and we
divided the patients into 2 subgroups; those who presented
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Decreased Expression of Angiogenin in the Eutopic Endometrium
from Women with Advanced Stage Endometriosis
Angiogenin, a potent inducer of angiogenesis, is expressed in human endometrium.
This study was performed to compare the expression of angiogenin mRNA level in
the eutopic endometrium from women with and without endometriosis. Thirty-two
women with advanced stage endometriosis and 29 control women were recruited.
Following isolation of total RNA from endometrial tissue and reverse transcription,
cDNA samples were amplified by real time polymerase chain reaction to quantify
the expression of angiogenin genes. In selected patients, immunohistochemical
staining was utilized to localize the area of angiogenin expression. Angiogenin
mRNA level was significantly lower in the endometriosis group than in the control
group during the secretory phase, especially the mid-secretory phase, and the
decline was observed mainly in the women who presented with infertility. Within
the endometriosis group, angiogenin mRNA levels did not differ between the prolif-
erative and secretory phases, but, in the control group, the level in the secretory
phase was higher than that during the proliferative phase. Immunohistochemistry
showed that the glandular epithelial cell layer was decorated positively in both groups.
These findings suggest that the relative deficiency of angiogenin expression in the
secretory endometrium could impair implantation in women with advanced stage
endometriosis. 
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with infertility and those who presented with problems other
than infertility. Endometrial samples were obtained either
by using a curette after pelviscopy or by opening the uterine
cavity immediately after hysterectomy. The review board for
human research of Seoul National University Hospital approv-
ed this project, and written informed consent for use of the
endometrium was obtained from each woman. All sections
were dated by a gynecological pathologist according to the
histological criteria of Noyes (7) and were classified as early
proliferative (days 4-7), mid proliferative (days 8-10), late
proliferative (days 11-14), early secretory (days 15-18), mid
secretory (days 19-22) or late secretory (days 23-28) phases.
All patients in the study had regular menstrual cycles and
had not received any hormonal therapy during the previous
6 months. The clinical characteristics, the menstrual phases
of each group, and the stages of endometriosis are summa-
rized in Table 1. Patients with a previous history of infertility
and histological or sonographic evidence of adenomyosis or
submucous myoma, which might be associated with infer-
tility, were excluded from the control group. The indications
for surgery amongst the control group were benign ovarian
cyst (n=14), carcinoma in situ of the uterine cervix (n=10),
and uterine intramural leiomyoma (n=5). There were no
significant differences in age between the two groups, but
the average number of deliveries was significantly lower in
the endometriosis group (p<0.05). 
RNA extraction, reverse transcription (RT), and real-time
PCR
Endometrial tissues used for mRNA extraction were snap-
frozen in liquid nitrogen and stored at -70℃ until analyzed.
The tissues for immunohistochemical staining were immersed
in OCT compound (Tissue Tek, Elkhart, IN, U.S.A.) and
stored at -70℃until analyzed. Total RNA was isolated using
Trizol reagent (Life Technologies Inc, Rockville, MD, U.S.A.)
according to the manufacturer’s protocol and stored at -70℃.
RT was performed using the Promega Reverse Transcription
System (Promega, Madison, WI, U.S.A.). Real-time PCR
was used for relative gene expression using an ABI Prism
7700 Sequence Detection System Thermal Cycler (Applied
Biosystems, Foster City, CA, U.S.A.). Primers and probes
were designed using Primer Express 1.5 Software and syn-
thesized commercially (Applied Biosystems). The primer
and probe sequences for angiogenin are shown in Table 2,
and commercially synthesized primer and probe were used
for glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(Human GAPDH Endogenous Control, Applied Biosys-
tems).
The optimal concentrations of all primers and probes were
determined according to the optimization protocol provid-
ed by Applied Biosystems. A stock placental cDNA pool
was prepared as a standard and used for all real-time assays.
PCR reaction mixes for each standard and samples were pre-
pared in separate tubes, using TaqMan Universal PCR mas-
ter mix, primers, probe and cDNA. All samples were assayed
in triplicate, and 25 μ L aliquots were transferred to wells of a
MicroAmp optical 96-well reaction plate (Applied Biosys-
tems). The thermocycler parameters were 50℃ for 2 min
and 95℃ for 10 min, followed by 40 cycles of 95℃ for 15
sec and 60℃for 1 min. A GAPDH pre-designed assay from
Applied Biosystems was used to measure the expression of
the housekeeping gene GAPDH in each sample using the
same standard preparation. Angiogenin gene expression was
normalized with GAPDH gene expression in each sample
and the ratio between angiogenin and GAPDH was expressed
as angiogenin mRNA level in all samples. 
Immunohistochemistry
We selected 2 endometrial samples in each menstrual phase
for the endometriosis and control group. Immunohistochem-
ical staining was performed as previously described by Koga
et al. (6). Briefly, 6 μ m cryostat sections cut from frozen tis-
sues were mounted on poly-L-lysine-treated slides, fixed in
cold acetone at -20℃for 10 min, and treated with 3% hydro-
gen peroxide for 10 min to eliminate endogenous peroxi-
dases. The sections were incubated with mouse monoclonal
antibody to human angiogenin (1:25; Biogenesis, Poole,
U.K.) overnight at 4℃. Control slides were incubated with
nonimmune mouse IgG, at a concentration adjusted to that
*, Values are mean±S.E.; 
� , p<0.05; 
� , Number of patients who present-
ed with infertility.
PCR, polymerase chain reaction; FAM, 6-carboxy-fluorescein; TAMRA,
6-carboxytetra methyl-rhodamine.
Endometriosis group
(n=32)
Control group
(n=29)
Age* 36.3±1.1 36.8±1.2
No. of deliveries* 0.9±0.2
� 1.8±0.8
�
Menstrual phase
Early proliferative 5 (3
� )7
Mid-proliferative 4 (2
� ) 7
Late proliferative 4 (1
� ) 4
Early secretory 4 (2
� ) 0
Mid-secretory 6 (4
� ) 5
Late secretory 9 (4
� ) 6
Table 1. Clinical characteristics of patients and controls
Sequence of primer and Taqman probe
Forward 5′ TGTCCTTGCCTTCCATTTCC 3′
Backward 5′ CTTTGGGCCCTTGGCAAT 3′
Probe FAM (reporter dye)
-CTGCACCCAGAACAGTGGTGGCAA
-TAMRA (quencher dye) 
Table 2. Sequence of primer and Taqman probe for real-time
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of the primary antibody. The sections were incubated with
biotinylated horse antimouse IgG, followed by avidin per-
oxidase and diaminobenzidine, using the Vectastain Elite
ABC kit (Vector Laboratories, Inc., Burlingame, CA, U.S.A.).
All sections were counterstained with hematoxylin. As the
primary purpose of immunohistochemical staining was to
localize the area of angiogenin expression in the control and
endometriosis group, we did not perform semiquantitative
comparison between the two groups. Assessments of immu-
nostaining were based on agreement among three indepen-
dent observers who were blinded as to which sections were
from patients with endometriosis and which were from con-
trol patients.
Statistical analysis
Comparisons of age, number of deliveries, and angiogenin
mRNA level between two groups were performed using the
Mann-Whitney U test for nonparametric data. Angiogenin
mRNA levels within the endometriosis or control group
were compared among the 5 or 6 different menstrual phases
using the Kruskal-Wallis test, followed by the Mann-Whit-
ney U test with Bonferonni correction, if significant. Angio-
genin mRNA levels within the control group were compared
among the 3 different subgroups according to the diagnosis
using the Kruskal-Wallis test. Results with p<0.05 were
considered significant.
RESULTS
The overall mean levels of angiogenin mRNA across all
phases were not significantly different between the endome-
triosis and the control groups (0.80±0.19 vs. 1.43±0.40,
mean±SEM). While there was no significant difference in
the proliferative phase (0.92±0.44 vs. 0.96±0.28), the
mean level of angiogenin mRNA was significantly lower
during the secretory phase in the endometriosis group com-
pared with the control group (0.72±0.14 vs. 2.21±0.92,
p<0.05). Within the endometriosis group, the mean level of
angiogenin mRNA did not differ between the proliferative
and secretory phase (0.92±0.44 vs. 0.72±0.14), but, in
the control group, the mean level of angiogenin mRNA in
the secretory phase was significantly higher compared with
that in the proliferative phase (0.96±0.28 vs. 2.21±0.92,
p<0.05) (Fig. 1). The mean levels of angiogenin mRNA
expression in the early, mid, and late proliferative and late
secretory phases were not different in the endometriosis group
compared with the respective phases in the control group,
but, in the mid-secretory phase, the mean level was signifi-
cantly lower in the endometriosis group than in the control
group (0.55±0.16 vs. 1.69±0.45, p<0.05). The levels of
angiogenin mRNA were not different among the 6 differ-
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Fig. 1. Relative expression of angiogenin in the eutopic endometrium of women with and without endometriosis during menstrual phases. 
*, Significant difference between proliferative and secretory phases (p<0.05); 
� ,� , Significant difference between patients and controls (p<0.05). 
All data are expressed as mean±SEM.
WP, whole menstrual phase; P, proliferative phase; S, secretory phase; EP, early proliferative phase; MP, mid-proliferative phase; LP, late
proliferative phase; ES, early secretory phase; MS, mid-secretory phase; LS, late secretory phase.
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Fig. 2. Relative expression of angiogenin in the eutopic endometri-
um of women with and without endometriosis during the mid and
late secretory phases. 
*,� , Significant difference between controls and patients with en-
dometriosis who presented with infertility (p<0.05). 
*
*
�
�
Control
Patients with endometriosis who 
presented with infertility
Patients with endometriosis who presented 
with problems other than infertilityAngiogenin in Endometriosis 805
ent phases within the endometriosis group and the 5 differ-
ent phases within the control group (Fig. 1).
When the endometriosis group is divided into 2 subgroups,
the statistically significant decline was observed only in the
women who presented with infertility compared with the
control group during the secretory and mid-secretory phases
(0.64±0.19 vs. 2.21±0.92, p<0.05; 0.40±0.15 vs. 1.69
±0.45, p<0.05, respectively) (Fig. 2). However, there were
no diffefences in mean levels of angiogenin mRNA expres-
sion between the two groups.
Immunohistochemical staining for angiogenin in the
endometrium showed that the glandular epithelial cell layer
and the stroma were decorated positively in both groups
and that the localization of positive staining was not differ-
ent between the two groups (Fig. 3). 
DISCUSSION
Endometrial changes related to angiogenesis are associat-
ed with ovulation and serve to prepare a receptive nidation
site for the embryo (8). Expression of vascular endothelial
growth factor (VEGF) is increased in the secretory phase
endometrium due to the effect of ovarian steroid hormones
(9-11). Progesterone has been shown to increase expression
of the endometrial VEGF189 isoform during the secretory
phase of the menstrual cycle, and native VEGF189 has been
observed to increase capillary permeability, which is neces-
sary for implantation and possibly for the maintenance of
pregnancy (12). 
The findings of the present study suggest that the normal
increase in angiogenin expression failed to occur during the
implantation window period in the eutopic endometrium
from women with advanced stage endometriosis. It is possi-
ble that a relative deficiency of angiogenin expression in
patients with advanced stage endometriosis leads to a defect
in the angiogenic process that is essential for successful implan-
tation. At present, however, it is unclear whether the rela-
tive deficiency of angiogenin expression in the secretory phase
is inherent to the eutopic endometrium itself or the secondary
consequence of other factors associated with ovarian endometri-
oma. In addition, it has to be clarified whether angiogenin
Fig. 3. Immunohistochemical stains for angiogenin in the endometrium of the mid- secretory phase. Glandular epithelial cell layer is deco-
rated positively (arrows) in both groups and the localization of positive staining was not different between the two groups. 
(A) Control (Magnification, ×200), (B) Control (Magnification, ×400), (C) Endometriosis (Magnification, ×200), (D) Endometriosis (Mag-
nification, ×400).
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itself plays a critical role in the implantation window period
or the expression of angiogenin in endometrial tissue is an
epiphenomenon accompanying another critical event in the
implantation window period. Further studies utilizing in
vitro cell culture or animal models for analyzing the expres-
sion level of angiogenin and other established markers for
implantation could give a correct answer to this issue.
Our results are in disagreement with recent reports (13,
14) demonstrating significant increases of angiogenin in the
serum and peritoneal fluid in patients with endometriosis.
Although it is very difficult to explain about the disagree-
ment, it is possible that the expression of angiogenin in the
eutopic endometrium is not regulated by the factors modu-
lating the levels of circulating angiogenin. Alternatively, the
elevated angiogenin levels in the peritoneal fluid of women
with endometriosis may result from the inflammation pro-
cesses associated with endometriosis. Despite lack of data, it
may also be speculated that an increased level of angiogenin
in the circulating blood or peritoneal fluid promote the estab-
lishment of endometriotic lesions in the pelvic cavity, and
once endometriotic lesions have been established and pro-
gressed to advanced stage, unknown adverse events, such as
impairment of luteal steroidogenesis or release of local inflam-
matory mediators inhibiting response to progesterone, reduce
the expression of angiogenin in the eutopic endometrium. 
Although the findings of the present study are novel, they
may have several weaknesses. First, in the present study,
immunohistochemistry was performed only in selected pati-
ents due to limited numbers of samples prepared, which
made it impossible to evaluate intensity differences between
the two groups with statistical comparisons. Second, we sim-
ply divided the endometriosis group into 2 subgroups only
according to the chief complaints; women who presented
with infertility and those who presented with problems other
than infertility. One may argue that this comparison is mean-
ingless since most women who presented with problems
other than infertility can be proven to be infertile after long
term follow-up or extensive work-up. Being well aware of
the argument, we compared the level of angiogenin expres-
sion to evaluate whether there is a subtle difference between
the two groups since some patients with endometriotic cyst
can conceive easily without any treatment. Further, well-
defined studies recruiting adequate number of patients with
full information about fertility status can give a correct answer
to these issues.
We designed this study as testing our hypothesis only in
patients with stage III/IV endometriosis, as it was very dif-
ficult to recruit adequate number of histologically confirmed
patients with stage I/II endometriosis. It is possible that the
expression of angiogenin in the eutopic endometrium might
be quite different between the patients with stage I/II and
III/IV endometriosis, considering that immune status, role
of growth factors, and pathogeneses are notably different for
stage I/II and III/IV endometriosis (15-17).
Despite these limits, we have found that the expression of
angiogenin is decreased in the eutopic endometrium from
women with advanced stage endometriosis during the nor-
mal window of implantation. Although further studies are
required to elucidate the relevance of angiogenin to the pro-
cess of implantation, these findings suggest that the relative
deficiency of angiogenin expression could be one of the crit-
ical factors involved in the mechanism by which endometrio-
sis impairs fertility.
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